Endoscopy 2012; 44(11): 993-997
DOI: 10.1055/s-0032-1325678
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Prevalence of buried Barrett’s metaplasia in patients before and after radiofrequency ablation

J. Yuan
1   Department of Internal Medicine, Banner Good Samaritan Medical Center, Phoenix, Arizona, USA
,
J. C. Hernandez
2   Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
S. K. Ratuapli
2   Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
K. C. Ruff
2   Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
G. De Petris
3   Department of Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
D. M. Lam-Himlin
3   Department of Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
G. E. Burdick
2   Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
R. Pannala
2   Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
F. C. Ramirez
2   Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
,
D. E. Fleischer
2   Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 23. August 2011

accepted after revision 25. Mai 2012

Publikationsdatum:
29. Oktober 2012 (online)

Background and study aim: Radiofrequency ablation (RFA) to treat Barrett’s esophagus is increasingly accepted. Description of the etiology, natural history, and prevalence of buried Barrett’s metaplasia (BBM) following RFA is limited, although BBM continues to pose a clinical dilemma. We aimed to assess the prevalence, characteristics, and eradication rate of BBM in patients with both dysplastic and nondysplastic Barrett’s esophagus, treated with RFA and followed over time.

Patients and methods: The presence of Barrett’s esophagus, dysplasia, and BBM, before and after RFA, was assessed by two gastrointestinal pathologists in a retrospective chart review of patients who had undergone RFA at our center and had completed appropriate follow-up. 

Results: We identified 112 patients with completed treatment and no further planned RFA. In 108, no residual Barrett’s esophagus was seen after RFA; 4 patients with persistent Barrett’s tissue underwent surgery. Regarding BBM, 17 /112 patients (15.2 %) had evidence of BBM during evaluation. In 12 /17 (70.5 %) BBM was found during the RFA treatment, with 8 having previously undergone non-RFA therapy and RFA for Barrett’s esophagus and 4 having no previous intervention. In 5 /17 (29.4 %), BBM was seen only after RFA monotherapy. All 17 showed no evidence of BBM at final evaluation and were classified in the complete remission group (108 /112).

Conclusion: Both Barrett’s esophagus and BBM were completely eradicated in all patients with long-term follow-up after RFA. Almost half of the patients with BBM had a prior history of non-RFA therapy for Barrett’s esophagus compared with 26 % the non-BBM cohort. All patients with previously identified Barrett’s esophagus and BBM were completely cleared of disease at final follow-up.

 
  • References

  • 1 Rees JR, Lao-Sirieix P, Wong A et al. Treatment for Barrett’s oesophagus. Cochrane Database Syst Rev 2010; CD004060 (01)
  • 2 Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-1383
  • 3 Spechler SJ, Sharma P. American Gastroenterological Association et al. American Gastroenterological Association Medical Position Statement on the Management of Barrett’s Esophagus. Gastroenterology 2011; 140: 1084-1091
  • 4 Sharma P, Falk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
  • 5 Fleischer DE, Sharma VK. Endoscopic ablation of Barrett’s esophagus using the Halo System. Dig Dis 2008; 26: 280-284
  • 6 Sharma P, Falk G, Sampliner R et al. Management of nondysplastic Barrett’s esophagus: Where are we now?. Am J Gastroenterol 2009; 104: 805-808
  • 7 Wang KK, Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 2008; 103: 788-797
  • 8 van Vilsteren FG, Bergman JJ. Endoscopic therapy using radiofrequency ablation for esophageal dysplasia and carcinoma in Barrett’s esophagus. Gastrointest Endosc Clin N Am 2010; 20: 55-74 , vi
  • 9 Fleischer DE, Odze R, Overholt BF et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett’s esophagus. Dig Dis Sci 2010; 55: 1918-1931 . Epub 2010 Apr 20
  • 10 Adler DC, Zhou C, Tsai TH et al. Three-dimensional optical coherence tomography of Barrett’s esophagus and buried glands beneath neosquamous epithelium following radiofrequency ablation. Endoscopy 2009; 41: 773-776
  • 11 Kelty CJ, Ackroyd R, Brown NJ et al. Endoscopic ablation of Barrett’s oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004; 20: 1289-1296
  • 12 Fleischer DE, Overhold BG, Sharma VK et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010; 42: 781-789
  • 13 Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288
  • 14 Basu KK, Pick B, Bale R et al. Efficacy and one year follow-up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium. Gut 2002; 51: 776-780
  • 15 Hornick J, Blount P, Sanchez C et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett’s esophagus. Am J Surg Pathol 2005; 29: 372-380
  • 16 Sampliner RE, Faigel D, Fennerty MB et al. Effective and safe reversal of nondysplastic Barrett’s esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc 2001; 53: 554-558
  • 17 Van Laetham JL, Penny MO, Salmon I et al. Intramucosal adenocarcinoma arising under squamous re-epithilisation of Barrett’s oesophagus. Gut 2000; 46: 547-577
  • 18 Mino-Kenudso M, Ban S, Ohana M et al. Buried dysplasia and early adenocarcinoma arising in Barrett’s oesphagus after porphimer-polydynamic therapy. Am J Surg Pathol 2007; 3: 403-409
  • 19 Ganz RA, Overholt BF, Sharma VK. U.S. Multicenter Registry et al. Circumferential ablation of Barrett’s esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 2008; 68: 35-40
  • 20 Sharma VK, Wang KK, Overholt BF et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65: 185-195
  • 21 Sharma VK, Jae Kim H, Das A et al. Circumferential and focal ablation of Barrett’s esophagus containing dysplasia. Am J Gastroenterol 2009; 104: 310-317
  • 22 Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68: 867-876
  • 23 Sharma VK, Kim HJ, Das A et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 2008; 40: 380-387